LEXINGTON, Mass., April 10, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today that Orin Bloch, MD, Clinical Instructor, Department of Neurological Surgery, University of California San Francisco (UCSF), will present an abstract that reports on outcomes with HSPPC-96 vaccination in patients with newly diagnosed glioma at the 81 st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in New Orleans, Louisiana, April 27-May 1, 2013. Dr. Bloch's presentation will be given during Plenary Session III of the AANS meeting on May 1, 2013 at 10:19 am ET.
Dr. Bloch is a lead medical scientist working on the study at UCSF. Dr. Parsa, MD, Ph.D., who is currently at UCSF and will soon join Northwestern University as the newly appointed Chair of the Department of Neurological Surgery, is the lead clinical investigator for Prophage Series G-100 and G-200 in newly diagnosed and recurrent glioblastoma, respectively.
HSP Platform: The Prophage Series Cancer VaccinesThe Prophage Series of vaccines are patient-specific therapeutic cancer vaccine candidates. They contain heat shock protein gp96 and associated peptides that are purified from patient tumor tissue. Prophage Series vaccines are designed to target only cancerous cells, not healthy normal cells, and limit the toxicities associated with traditional broad-acting cancer treatments. Prophage Series G-100 and G-200 are being studied in two different settings of glioma: newly diagnosed and recurrent disease. Glioma is the deadliest form of brain cancer with an average survival of six to 14 months. Promising results from an earlier Phase 2 trial in patients with recurrent glioma treated with Prophage Series G-200 were presented at the 2012 AANS Annual Meeting. In the 2012 AANS presentation, over 40 patients were treated and the population evaluated for efficacy had a median Karnofsky performance status (KPS) of 80 and median age of 53. Patients treated with G-200 lived significantly longer than 86 consecutive patients not enrolled in the G-200 clinical trial, but treated with alternative therapies during the study period.